Trial Profile
Phase I Clinical Study of Combination Therapy with Eribulin and Capecitabine in Patients with Progressive Recurring Breast Cancer(JBCRG-18Cape)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 22 Jul 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 25 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 30 Dec 2013 Planned number of patients changed from 6 to 9 as reported by University Hospital Medical Information Network - Japan.